GenIbet : a biopharmaceutical contract manufacturing start-up
Autor(a) principal: | |
---|---|
Data de Publicação: | 2015 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.14/17322 |
Resumo: | The thesis that is by this means present under the form of a case study intends to emphasize the challenges faced by a Portuguese start-up, Genibet, upon its initial years of operations and the need to grow internationally. The case study may also be used as a learning tool, once it enables instructors and students to apply strategic knowledge and frameworks on a real life situation of a company. Genibet is a biopharmaceutical contract manufacturing organization that provides cell, bacterial and viral production services to biopharmaceutical companies and clinical research institutes. Genibet’s services comprise the production of cell banks, virus banks, plasmid DNA, polysaccharides, vaccines and virus with therapeutic activity, recombinant proteins, cells for cell therapy and virus like particles. After analyzing the environment of the bio-CMOs industry, we were able to make some important keynotes: The biopharmaceutical CMO market amounted to over $ 3 billion in 2013 compared to approximately $ 2 billion in 2011. Regarding the two production segments within the whole market, the most relevant one is the animal cells segment (mammalian) since it is expected to have a CAGR of 14,2% (2011- 2018) against a CAGR in between 10%-15% of the whole market. To address start-ups and clinical/research groups needs, the more adequate providers are the small contract manufacturing organizations since they have just the right size and capacity. The regions in the world with emergent countries are where the industry will experience greater growth, meaning that the larger CMOs will tend to move to those places. For the small-medium CMOs will be left to cover the mature regions where the growth will not be as fast – Europe and US. The aim of the case study was to scrutinize Genibet’s current situation and strategy in order to find some possible improvement solutions for the coming years. Together with a mission to offer customers excellency and flexibility of services that will provide evolution of biological investigation, the company’s values rely on “Safety, Commitment, Excellence, Flexibility and Groupwork”. Thus, three segments were analyzed: Client segments, Production Segments and Geographic Segments. The hereby displayed case is based on a small company’s real life situation and its efforts to stay on the market through competitive advantage generated by its different Business Model structure. |
id |
RCAP_07fb9990e71fe73d9c87489532050b4a |
---|---|
oai_identifier_str |
oai:repositorio.ucp.pt:10400.14/17322 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
GenIbet : a biopharmaceutical contract manufacturing start-upDomínio/Área Científica::Ciências Sociais::Economia e GestãoThe thesis that is by this means present under the form of a case study intends to emphasize the challenges faced by a Portuguese start-up, Genibet, upon its initial years of operations and the need to grow internationally. The case study may also be used as a learning tool, once it enables instructors and students to apply strategic knowledge and frameworks on a real life situation of a company. Genibet is a biopharmaceutical contract manufacturing organization that provides cell, bacterial and viral production services to biopharmaceutical companies and clinical research institutes. Genibet’s services comprise the production of cell banks, virus banks, plasmid DNA, polysaccharides, vaccines and virus with therapeutic activity, recombinant proteins, cells for cell therapy and virus like particles. After analyzing the environment of the bio-CMOs industry, we were able to make some important keynotes: The biopharmaceutical CMO market amounted to over $ 3 billion in 2013 compared to approximately $ 2 billion in 2011. Regarding the two production segments within the whole market, the most relevant one is the animal cells segment (mammalian) since it is expected to have a CAGR of 14,2% (2011- 2018) against a CAGR in between 10%-15% of the whole market. To address start-ups and clinical/research groups needs, the more adequate providers are the small contract manufacturing organizations since they have just the right size and capacity. The regions in the world with emergent countries are where the industry will experience greater growth, meaning that the larger CMOs will tend to move to those places. For the small-medium CMOs will be left to cover the mature regions where the growth will not be as fast – Europe and US. The aim of the case study was to scrutinize Genibet’s current situation and strategy in order to find some possible improvement solutions for the coming years. Together with a mission to offer customers excellency and flexibility of services that will provide evolution of biological investigation, the company’s values rely on “Safety, Commitment, Excellence, Flexibility and Groupwork”. Thus, three segments were analyzed: Client segments, Production Segments and Geographic Segments. The hereby displayed case is based on a small company’s real life situation and its efforts to stay on the market through competitive advantage generated by its different Business Model structure.A tese que é por este meio apresentada sob a forma de Case de Estudo, tem como objective enfatizar os desafios enfrentados por um start-up Portuguesa, Genibet, durante os seus primeiros anos de operações e a necessidade da mesma de crescer a nível intrenacional. O Caso de Estudo pode para além do mais ser usado como ferramenta de aprendizagem, uma vez que permite ao professor e aos alunos aplicar conhecimento estratégico e quadros de aprendizafem na situação real de uma empresa. A Genibet é uma empresa que fabrica produtos biofarmacêuticos ara terceiros (Contract Manufacturing Organization – CMO) que oferece serviços de cultura de células e bactérias, bem como o desenvolvimento do processo viral. Os seus serviços incluem especificamente a produção de bancos de células, virus, DNA plasmídeo, polissacarídeos, vacinas e vírus com actividade terapêutica, proteínas recombinantes, células para terapia e vírus como partículas. Após uma análise do ambiente da indústria de CMOs biofarmacêuticas, for possível reter algumas ideias-chave: O mercado CMO biofarmacêutico foi avaliado em $ 3 biliões em 2013, em comparação com apenas $ 2 biliões em 2011. No que diz respeito aos segementos de produção existentes no mercado em geral, o mais relevante é o segmento de células animas (mammalian) uma vezt que este tem uma CAGR esperada de 14,2% entre 2011 e 2018, contra uma CAGR de 10%-15% do mercado em geral. Para responder às necessidades de start-ups e grupos clínicos e de investigação, os fornecedores mais adequados são as pequenas empresas de produção sub-contratada, já que estas apresentam a dimensão e capacidade certas. As regiões a nível mundias que incluem países em desenvolvimentos são aquelas que expericiarão maior crescimento. Isto significa que as empresas maiores terão tendência em mudar-se para estes sítios. Para as CMOs de pequena e média dimensão, ficarão disponíveis as regiões que já atingiram maturidade e que, como tal, não apresentam um crescimento tão acelerado. O propósito do Caso de Estudo for aprofundar a situação actual da Genibet bem como a sua estratégia por forma a descobrir potenciais melhoramentos para os próximos anos. A par com uma missão de oeferecer aos clientes excelência e flexibilidade de serviços que providenciarão evolução biológica, os valores da empresa assentam em “Segurança, Compromisso, Excelência, Flexibilidade e Trabalho de Equipa”. Desta forma, três segmenstos foram analisados: Segmentos ao nível de clientel, Segmentos de Produção e Segmentos Geográficos. O caso aqui proposto é então baseado na situação real de uma empresa e os seus esforços para se manter no mercado através de vantagem competitiva pela diferente estrutura que o seu Modelo de Negócio apresenta.Pinheiro, Susana Frazão Ferreira FernandesVeritati - Repositório Institucional da Universidade Católica PortuguesaAlves, Sara Brites2015-04-27T13:50:57Z2015-02-1620152015-02-16T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10400.14/17322TID:201171988enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-26T01:36:50Zoai:repositorio.ucp.pt:10400.14/17322Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:14:31.512873Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
GenIbet : a biopharmaceutical contract manufacturing start-up |
title |
GenIbet : a biopharmaceutical contract manufacturing start-up |
spellingShingle |
GenIbet : a biopharmaceutical contract manufacturing start-up Alves, Sara Brites Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
title_short |
GenIbet : a biopharmaceutical contract manufacturing start-up |
title_full |
GenIbet : a biopharmaceutical contract manufacturing start-up |
title_fullStr |
GenIbet : a biopharmaceutical contract manufacturing start-up |
title_full_unstemmed |
GenIbet : a biopharmaceutical contract manufacturing start-up |
title_sort |
GenIbet : a biopharmaceutical contract manufacturing start-up |
author |
Alves, Sara Brites |
author_facet |
Alves, Sara Brites |
author_role |
author |
dc.contributor.none.fl_str_mv |
Pinheiro, Susana Frazão Ferreira Fernandes Veritati - Repositório Institucional da Universidade Católica Portuguesa |
dc.contributor.author.fl_str_mv |
Alves, Sara Brites |
dc.subject.por.fl_str_mv |
Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
topic |
Domínio/Área Científica::Ciências Sociais::Economia e Gestão |
description |
The thesis that is by this means present under the form of a case study intends to emphasize the challenges faced by a Portuguese start-up, Genibet, upon its initial years of operations and the need to grow internationally. The case study may also be used as a learning tool, once it enables instructors and students to apply strategic knowledge and frameworks on a real life situation of a company. Genibet is a biopharmaceutical contract manufacturing organization that provides cell, bacterial and viral production services to biopharmaceutical companies and clinical research institutes. Genibet’s services comprise the production of cell banks, virus banks, plasmid DNA, polysaccharides, vaccines and virus with therapeutic activity, recombinant proteins, cells for cell therapy and virus like particles. After analyzing the environment of the bio-CMOs industry, we were able to make some important keynotes: The biopharmaceutical CMO market amounted to over $ 3 billion in 2013 compared to approximately $ 2 billion in 2011. Regarding the two production segments within the whole market, the most relevant one is the animal cells segment (mammalian) since it is expected to have a CAGR of 14,2% (2011- 2018) against a CAGR in between 10%-15% of the whole market. To address start-ups and clinical/research groups needs, the more adequate providers are the small contract manufacturing organizations since they have just the right size and capacity. The regions in the world with emergent countries are where the industry will experience greater growth, meaning that the larger CMOs will tend to move to those places. For the small-medium CMOs will be left to cover the mature regions where the growth will not be as fast – Europe and US. The aim of the case study was to scrutinize Genibet’s current situation and strategy in order to find some possible improvement solutions for the coming years. Together with a mission to offer customers excellency and flexibility of services that will provide evolution of biological investigation, the company’s values rely on “Safety, Commitment, Excellence, Flexibility and Groupwork”. Thus, three segments were analyzed: Client segments, Production Segments and Geographic Segments. The hereby displayed case is based on a small company’s real life situation and its efforts to stay on the market through competitive advantage generated by its different Business Model structure. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-04-27T13:50:57Z 2015-02-16 2015 2015-02-16T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.14/17322 TID:201171988 |
url |
http://hdl.handle.net/10400.14/17322 |
identifier_str_mv |
TID:201171988 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131823909896193 |